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We investigated whether genetic lesions such as loss of heterozygosity (LOH) are detected in prostatic cells obtained by prostatic
massage during early diagnosis of prostate cancer (CaP) and discussed their clinical relevance. Blood and first urine voided after
prostatic massage were collected in 99 patients with total prostate-specific antigen (PSA) between 4 and 10ngml
 1, prior to prostate
biopsies. Presence of prostatic cells was confirmed by quantitative RT–PCR analysis of PSA mRNA. Genomic DNA was analysed for
LOH on six chromosomal regions. One or more allelic deletions were found in prostatic fluid from 57 patients analysed, of whom 33
(58%) had CaP. Sensitivity and specificity of LOH detection and PSA free to total ratio o15% for positive biopsy were respectively
86.7 and 44% (P¼0.002) for LOH, and 55 and 74% (P¼0.006) for PSA ratio o15%. Analysis of LOH obtained from prostatic
tumours revealed similar patterns compared to prostatic fluid cells in 86% of cases, confirming its accuracy. The presence of LOH of
urinary prostatic cells obtained after prostatic massage is significantly associated with CaP on biopsy and may potentially help to
identify a set of patients who are candidates for further prostate biopsies.
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Prostate cancer (CaP) is one of the most common cancers in men
in Western countries and is second in terms of mortality (Greenlee
et al, 2000). During the year 2000, in Europe, 189466 new cases of
CaP were diagnosed with 81 353 CaP-related deaths. In order to
reduce mortality, prostate cancer should be diagnosed at an early
stage when the tumour is still organ confined. Whereas the
treatment of advanced CaP is inefficient, an organ-confined
tumour can be cured by radical prostatectomy, radiotherapy or
cryotherapy.
The early detection of CaP is actually carried out by the
association of digital rectal examination (DRE) and serum total
prostate-specific antigen (tPSA) level. The usual upper limit for
tPSA is 4ngml
 1. However, between 4 and 10ngml
 1, there exists
a diagnostic grey zone with an estimated probability of only 40% of
CaP in men with normal findings on DRE. Prostrate cancer can
only be accurately differentiated from benign prostate hyperplasia
(BPH) by pathological proof, usually obtained by prostatic
biopsies (PB). To refine the indications for PB, and therefore to
reduce morbidity, new indicators based on tPSA were developed:
age-adjusted tPSA cutoffs, tPSA velocity or tPSA density where the
elevated tPSA is indexed to the gland size (Brawer, 1999). The most
commonly used indicator is free/total PSA ratio (f/tPSA), which
may help to predict CaP or BPH in its extreme values (Catalona
et al, 1997). However, the probability of CaP at biopsy among men
with a PSA value between 4 and 10ngml
 1 and normal findings on
DRE ranged from 56% for men with an f/tPSA ratio of o10% to
8% for men with a ratio 425% (Catalona et al, 1998), underlying
the lack of accuracy of the f/tPSA indicator. The difficulty of
estimating the risk of CaP when there is a suspicious DRE without
nodule, when tPSA ranges between 4 and 10ngml
 1 or when f/tPSA
has an average value (between 15 and 25%), taken together with
the morbidity due to PB, highlights the need of new predictive
markers for CaP.
Several authors have used prostatic fluid to develop new
diagnostic markers for CaP. Recently, investigators examined the
presence of glutathione S-transferase (GSTP1) hypermethylation in
shed neoplastic cells and urinary debris (Cairns et al, 2001).
However, its sensitivity (27%) is too low for clinical practice.
Telomerase activity was detected after prostatic massage in freshly
voided urine (Meid et al, 2001), but this approach did not reach
clinical practice because of low sensitivity (40%) for the detection
of low-grade tumours. The evaluation of ornithine-decarboxylase
(ODC) expression in prostatic fluid after prostatic massage has
shown an uptranscriptional regulation in CaP (Mohan et al, 1999),
but intraindividual variations have been observed. Interestingly,
the quantification in urine samples after prostatic massage of the
CaP-specific gene DD3 (PCA3) transcripts has shown a sensibility
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sand a specificity of respectively 67% and 83% (Hessels et al, 2003).
Presently, one limit of the clinical acceptance of tests based on
quantification of transcripts in urinary sample is the need to
preserve RNA quality and to manage immediate frozen sample in
clinical pratice. Urinary tests based on DNA sample, like
microsatellite analysis or FISH, have already shown their ability
to detect bladder carcinoma in clinical practice.
Loss of heterozygosity (LOH) is the most frequent genetic
abnormality in CaP. Recurrent LOH in CaP has been found on
chromosome arms 7q, 8p, lOq, 12p, 13q, 16q, 17q and 18q,
suggesting the presence of tumour suppressor genes (Gao et al,
1995; Latil et al, 1999; Elo and Visakorpi, 2001). Although these
tumour suppressor genes are unknown, we have previously shown
accurate detection of CaP by investigating genetic alterations in
prostatic cells collected in urinary sediments (Cussenot et al,
2001). Furthermore, prognostic significance has been associated
with deletions on chromosome 8p22, which predicts disease
progression (Matsuyama et al, 2001), and on 12pl2–13 and 13q,
which predicts aggressiveness (Dong et al, 2000; Kibel et al, 2000).
In order to extend our previous work (Fromont et al, 2003), the
aim of this study was to develop a new noninvasive method to
detect early stages of CaP using LOH analysis of 7q31, 8p22, 12pl3,
13ql4, 16q23.2 and 18q21. We have analysed these six regions in
prostatic cells collected in urinary sediments after prostatic
massage for LOH, and compared them with the f/tPSA values
and results of prostatic biopsy.
PATIENTS AND METHODS
Patients’ selection
Samples were collected in two separated centres. Men who
presented with suspected CaP requiring PB were included in this
study. CaP was suspected with a PSA 44ngml
 1 and/or
suspicious DRE. Patients with a tPSA over 10ngml
 1 or with
evident clinical T3 CaP at DRE were excluded, as well as men with
a history of urothelial tumours. Agreement for this clinical trial
was obtained from the ethics committee of Paris-StLouis (CCPPRB
No. 2000/69-29/12/2000). Informed consent was obtained from
each patient.
A total of 99 patients (mean: 65.4years; s.d.: 7.5) with a tPSA
(mean: 6.7ngml
 1; s.d.: 1.76) in the diagnostic grey zone (4–
10ngml
 1) were analysed for f/tPSA ratio (mean: 16.1; s.d.: 5.9)
and the presence of LOH in prostatic fluid cells. All had, at least
sextant, transrectal ultrasound-guided PB.
Sample collection
Venous blood was collected from each patient for both PSA
measurement and DNA extraction. Prostrate-specific antigen
measurements were performed in the Saint-Louis hospital depart-
ment of hormonal biology for every sample with PSA-RIACT and
FPSA-RIACT (CIS bio International, Gif-s/-Yvette, France).
Urinary sediments were obtained after prostatic massage
performed by DRE. Prostatic massage was performed in order to
obtain prostatic secretion at the urethral meat. The first urine
voided was collected to extract both RNA and DNA. Urinary
samples were centrifuged for 30min at 41C (850g), before the cell
pellets were immediately stored at  801C.
In 19 of these cases, formalin-fixed and paraffin-embedded
prostatic samples from the patient’s radical prostatectomy speci-
men were also analysed (Table 1). In six of these specimens, laser-
capture microdissection was used to obtain ‘normal’ prostatic
epithelial cells, close to the tumour, for LOH analysis. In each of
these samples, prostatic fluid cells and tumour were also analysed
(Table 1). Cells were catapulted in 20mlo f1  lysis buffer (for 1ml
of lysis buffer: Tris 2 M pH 8 25ml, EDTA 0.5 M 2ml, Tween 20 5ml,
proteinase K 50ml and H2O 918ml) (PALM Micro Laser
Technologies, Bernried, Germany).
PCR protocol and genotyping analysis are described below.
Nucleic acid extractions
All the products used in this study were from SIGMA, (St Louis,
MO, USA) unless specified otherwise.
Two distinct methods were used for blood lymphocyte DNA and
prostatic cell DNA extraction.
A cell lysis was obtained from blood by red corpuscle lysis
solution (Tris 2 M pH 7.6, NaCl 3 M, MgC12 1 M,H 2O). After
centrifugation (10min, 241C, 1200g), a white corpuscle lysis
solution (Tris 1 M pH 7, NaCl 3 M, EDTA 0.4 M, SDS 10%, H2O) was
added to the pellet; proteins were precipitated and pelleted by
centrifugation (10min, 241C, 1200g) with 10 M ammonium acetate.
DNA precipitation was obtained by adding cold isopropanol to the
supernatant. After centrifugation (5min and 1200g), the DNA
pellet was rinsed with 70% ethanol and recentrifuged. DNA was
suspended in TE 10-1 (Tris 2 M pH 7.6, EDTA 0.4 M,H 2O) under
slow agitation at 421C for 48h. DNA concentration was calculated
by spectrophotometry (DU 640 B, Beckman, USA) at 260nm and
adjusted to 200ngml
 1.
Prostatic cell DNA was obtained using phenol–acid/chloroform
extraction, after proteinase K treatment of the microdissected
tumour cells.
RNA extraction was performed only from urinary sediments
according to Chomczynski’s method (Chomczynski and Sacchi,
1987). RNA was stored at  801C in DEPC-treated water.
RNA analysis
To determine the presence of prostatic cells and their proportion
compared with other cell types, RNA analysis was performed by
quantitative real-time PCR after reverse transcription (RT).
After a first RNA incubation (1ml of total RNAs in 3ml DEPC
water for 5min at 571C), RT was performed with 16ml of reaction
mix (buffer 5  4ml, DTT 0.1mM 2ml, DNTP 10mM each 1ml, Rhex
6ml, RNAsin 0.5ml, Superscript II 0.5ml and H2O2 ml) by three
cycles of incubation: 10min at 201C, 30min at 421Ca n d5 m i na t
991C (Peltier Thermal Cycler-200, MJ Research, INC Massachussets,
USA).
Quantification of prostate-specific mRNA encoding PSA (50-acc
aga gga gtt ctt gac ccc aaa-30;5 0-ccc cag aat cac ccg agc ag-30) and
transcripts of PPIA (peptidylprolyl isomerase A gene encoding
cyclophilin A) gene, used as an endogenous RNA control (50-gtc
aac ccc acc gtg ttc tt -30;5 0-ctg ctg tct ttg gga cct tgt-30), was
performed by means of the SYBR
s Green PCR Core Reagents kit
(Applied Biosystems, Palo Alto, CA, USA) using an ABI Prism 7700
Sequence Detection System (Applied Biosystems, Palo Alto, CA,
USA). To determine which samples had a sufficient proportion of
prostatic cells for genetic analysis, we ensured that the PPIA and
PSA mRNA levels corresponded to a straight line (Ct PPIA¼0.386
Ct PSAþ13.82) (data not shown). In total, 82 samples contained a
satisfactory proportion of prostatic cells for genotyping analysis.
Genotyping analysis
Extracted DNA from blood and prostatic cells was amplified by
PCR, using 14 microsatellite markers localised on chromosome
arms 7q31, 8p22, 12pl3, 13ql4, 16q23.2. and 18q21: D7S480,
D7S522, D7S523, D8S261, D8S1786, D12S77, D12S358, D13S153,
D13S272, D13S284, D16S507, D16S518 (Dib et al, 1996), and
D18S39, D18S46 (Straub et al, 1993). PCR amplification was
carried out with 3ng of DNA in a 20ml final volume of reaction mix
(dNTP 0.25mM, Tris 1 M, boric acid 0.9 M, EDTA 0.01 M, 20 pmol of
each primer (MWG Biotech, Ebersberg, Germany), 0.75mlo f
DMSO, Taq polymerase 1U (Qbiogen, Illkirch, France)). The PCR
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sprotocol was previously described (Berthon et al, 1998) and
annealing temperature was optimised for each primer.
Then, 1ml of PCR product was added to 1ml of blue dextran and
3ml of formamide. After a 2min denaturation at 941C, amplified
fragments were analysed on an automatic sequencer (377 DNA
sequencer, Applied Biosystems, Palo Alto, CA, USA) by electro-
phoresis in TBE buffer (Tris 0.089 M, borate 0.089 M, EDTA 0.002 M
pH 8) through a 4% polyacrylamide (Acryl/Bisacryl 29/1) 6 M urea
gel. Analysis was performed by GeneScan 3.1 Fragment Analysis
Software (Applied Biosystems, Palo Alto, CA).
Loss of heterozygosity was considered to be present when the
relative intensity of the two alleles in urinary sample DNA differed
from the relative intensity in leuckocyte DNA by a factor of at least
1.3. This threshold, which is suitable for tumour LOH detection
(Zenklusen et al, 1994), can also be used for the urinary sediments
of this study because of the quality selection criteria applied on the
samples (see RNA analysis). Each LOH analysis was performed at
least twice (repeated PCR amplification, gel separation, and
quantification).
Statistical analysis
All statistical analyses were performed by using the w
2 test with the
SAS software (version 6.12;. SAS Institute Inc., Cary, NC, USA). All
P-values were determined by two-sided tests. P-values less than
0.05 were considered to be statistically significant.
RESULTS
Out of 99 patients included in this study, a set of 81 patients had a
sufficient proportion of prostatic cells in urinary sediment to
perform LOH analysis, of which 38 had CaP on PB (Tables 1 and
2). The distribution of age, tPSA and f/tPSA ratio in the group with
and without positive biopsy were: negative biopsy: age 65.2 s.d. 5.8;
tPSA 6.7 s.d. 1.8; f/tPSA 18.2 s.d. 6.0; positive biopsy: age 66.5 s.d.
9.2; tPSA 6.7 s.d. 1.7; f/tPSA 13.8 s.d. 5.3. Allelic deletions were
founded for 57 patients, of whom 33 (58%) had CaP. Within this
group, LOH detection had an 87% sensibility and 44% specificity
(Table 1).
Then, we checked the validity of the LOH test in urinary
sediments by comparing them with the LOH of the corresponding
tumours in 19 patients (Table 1). We defined three classes of
results: strictly identical results with the same patterns of LOH in
tumour and urinary sediments; concordant results in which
identical patterns were seen in the two samples except for
additional tumour LOH; discordant results corresponded to LOH
observed in urinary sediment but not in the tumour. The
comparison between the two samples has shown that identical
LOH was present in 70.6% and concordant results in 86%. Only
14% of the results were discordant (28.1% of them concerned the
16q23.2 region markers). We investigated also the hypothesis that
genetic alterations could exist prior to a morphological abnorm-
ality. Therefore, the genetic status of histologically ‘normal’
prostatic cells located near the tumour was analysed. In total,
Table 1 Results of the 14 loci tested on desquaming prostatic cell DNA according to PB results and in comparision with LOH in tumoral and nontumoral
DNA cells from prostate specimens
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s53.3% of allelic deletions observed in tumour DNA were present in
the histologically normal prostatic cells (Table 1).
Genetic diagnosis using LOH has been compared to f/tPSA
ratios of o25, o20 and o15%, which are considered as the best
indicators of CaP (Table 2). Only seven patients (8.6%) had an f/
tPSA ratio over two 5%, two of which had CaP. Using the o15%
cutoff, the f/tPSA ratio had a sensitivity of 50% and specificity of
77%, which discriminates significantly (P¼0.006) the group with
CaP (Table 3). All cancers could be detected if f/tPSA o15% or
LOH was used, and in these conditions the specificity was 32%.
Out of the 81 patients (of whom five had a CaP), 25 did not have
any LOH detected. In each case, they had an f/tPSA threshold
o15%. Of the 81 patients, 57 had one or more LOH, of which 31
had CaP. None of these patients had LOH in all six chromosomal
regions. The frequency of 1–3 chromosomal LOHs was not
significantly related to the presence of CaP. Of the patients, 56 and
61% respectively had positive biopsies among patients with (one or
two) LOH and over three altered regions.
DISCUSSION
By this clinical trial, using early CaP, we have shown that LOH can
be found in cells obtained from urine by prostatic massage. In
particular, LOH can be found at hotspot loci associated with CaP,
in patients with positive PB.
Assuming that a positive biopsy is the gold standard, the
statistical parameters of the CaP detection by the LOH analysis
showed 86.8% sensitivity for CaP detection. The fact that the
specificity was only 44% (24 false positives) might be due, in part,
to the low sensitivity of PB, which is currently estimated between
66 and 85%, and should be close to 83.3% for a CaP with a volume
greater than 2cm
3 (Terris, 1999). This sensitivity varies according
to the location of CaP inside the prostate (71.4% for the peripheral
zone cancers and 33.3% for the transition zone cancers).
Furthermore, the sensitivity increases by repeated biopsies,
underlying the fact that some CaP are missed by the first set of
biopsies. With reference to the experience of LOH detection in
urine during the follow-up of bladder cancer, the specificity should
improve with the patients’ clinical follow-up.
One of the limitations of the study was the small number of
prostate specimens available, as only 19 patients out of 99
underwent a radical prostatectomy. Therefore, the clinical
significance of the detected tumours according to tumour volume,
Gleason score and presence of adverse pathological patterns such
as presence of extracapsular extension and seminal vesicle
invasion was unknown.
The presence of genetic alterations in ‘normal’ cells located near
the tumour implies that this test may be useful to detect CaP at a
very early stage or to identify those patients at high risk of
developing CaP. Although the roles of multifocality (multiple foci
of carcinoma with independent origins) and clonality development
(multiple foci of carcinoma in the same prostate derived from a
single progenitor) in CaP are still not fully understood, only 11% of
LOH in normal tissue could not be found in the adjacent tumour,
suggesting a monoclonal expansion of cancerous cells. Hu ¨gel and
Wernert (1999) and Macintosh et al (1998) analysed LOH in
different areas of prostate tumour separated by microdissection.
They found that a significant proportion of CaP were made of
several histological patterns. However, the clonal or multifocal
origin of these patterns was not fully elucidated. Whereas each
tumour has its own pattern of LOH, different combinations of
genetic events could result in similar malignant phenotypes of CaP.
The sensitivity (87%) of LOH detection for CaP was higher than
that observed for the detection of telomerase activity (40%) by
Meid et al (2001) or for the detection of GSTPl hypermethylation
(27%) by Cairns et al (2001) or quantification of DD3 PCA3
transcripts (67%) (Hessels et al, 2003).
Some ‘false-negative’ patients had noninformative loci, because
of homozygosity for the marker. This lack of genetic information
affected the sensitivity and specificity of LOH analysis. We
analysed urinary samples for LOH at six different loci known to
be frequently altered in prostate tumours, but other chromosomal
regions like 16q22.1 have also been shown to be involved in CaP
genesis. The large majority of all molecular mechanisms explaining
prostate cancer development are still expected to be discovered.
In order to select those patients likely to have CaP, we have used
a noninvasive test based on LOH detection in cells from prostatic
fluid. Furthermore, besides diagnosis value, LOH detection could
Table 2 Pathological patterns of cancers on biopsies and markers (tPSA,
f/tPSA, number of LOH)
Age tPSA f/tPSA
Number
of LOH
Gleason
score from
biopsy Grade 1 Grade 2
Stage pT
a
from
biopsy
73 6 7 1 5 3 2 2a
84 8 20 2 7 4 3 2b
56 6 19 2 4 2 2 2a
63 7 15 2 6 3 3 2a
66 4 15 2 6 3 3 2a
58 6 8 2 6 3 3 2a
69 10 11 3 6 3 3 2b
81 7 11 1 6 3 3 2a
72 7 7 1 6 3 3 2a
75 6 16 1 6 3 3 2a
58 7 6 0 7 4 3 2b
61 8 27 1 4 2 2 2a
64 4 22 5 6 3 3 2a
68 7 7 1 6 3 3 2b
56 7 17 5 4 2 2 2a
57 6 25 5 6 3 3 2a
66 5 17 2 5 3 2 2a
59 8 15 3 4 2 2 2a
75 8 15 0 5 2 3 2b
72 6 14 1 5 2 3 2a
69 6 17 3 5 2 3 2a
73 9 10 2 8 4 4 2a
67 5 15 1 7 3 4 2b
56 6 10 2 7 4 3 2b
70 8 12 3 6 3 3 2a
56 6 7 2 6 3 3 2a
67 5 17 3 6 3 3 2a
93 5 8 1 8 4 4 2b
73 7 16 3 6 3 3 2a
66 4 15 4 6 3 3 2a
60 6 24 1 5 3 2 2a
58 6 17 1 7 4 3 2b
58 7 14 0 6 3 3 2a
70 8 13 3 7 4 3 2c
81 10 12 0 7 4 3 2c
69 8 13 2 6 3 3 2c
49 9 8 0 7 3 4 2c
59 10 8 2 5 2 3 2c
apT2a¼Positive biopsies in one prostatic lobe, less than half-lobe, pT2b¼positive
biopsies in one prostatic lobe, more than half-lobe, pT2c¼positive biopsies in the
two prostatic lobes (according to UICC, TNM 2002).
Table 3 Diagnostic parameters of the genetic test (LOH) and f/tPSA
ratios (threshold values: 15, 20 and 25 %) for 81 patients with a total PSA
between 4 and 10ngml
 1
Sensitivity % Specificity % v
2 (P-value)
Genetic test (LOH) 87 44 P¼0.002
f/tPSA o25% 95 12 P¼0.309
f/tPSA o20% 86 33 P¼0.09
f/tPSA o15% 55 74 P¼0.006
LOH or f/tPSA o15% 100 32 P¼0.06
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sbring prognostic information on CaP aggressiveness. A significant
correlation would exist between the presence of certain LOH and
relapse after radical prostatectomy. Current follow-up analysis is
under way.
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